Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 2/20 | 0.57 |
| ▸ | OPRL1 | P41146 | 5/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPC1L1 | Q9UHC9 | 11/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18973052 | 0.89 | BDKRB2 (0.73) | BDKRB2OPRL1OPRM1OPRK1MEN1 | |
| SCHEMBL18972830 | 0.89 | BDKRB2 (0.55) | BDKRB2OPRL1OPRM1OPRK1MEN1 | |
| SCHEMBL12315495 | 0.88 | OPRL1 (0.65) | BDKRB2OPRL1OPRM1OPRK1MEN1 | |
| SCHEMBL20187115 | 0.88 | BDKRB2 (0.59) | BDKRB2OPRL1OPRM1OPRK1MEN1 | |
| Hydrochloric Acid SCHEMBL17140435 | 0.88 | BDKRB2 (0.54) | BDKRB2OPRL1OPRM1OPRK1MEN1 | |
| SCHEMBL20187136 | 0.85 | MEN1 (0.66) | BDKRB2OPRL1OPRM1OPRK1MEN1 | |
| SCHEMBL17140929 | 0.82 | NPC1L1 (0.65) | BDKRB2OPRL1OPRM1OPRK1NPC1L1 | |
| SCHEMBL5100454 | 0.82 | BDKRB2 (0.55) | BDKRB2OPRL1OPRM1OPRK1MEN1 | |
| SCHEMBL6162185 | 0.80 | OPRL1 (0.61) | BDKRB2OPRL1OPRM1OPRK1MEN1 | |
| SCHEMBL13964071 | 0.80 | BDKRB2 (0.52) | BDKRB2OPRL1OPRM1OPRK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | X-RX, INC. (US) | 2018-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10011601-B2 | Substituted spirocyclic inhibitors of autotaxin | ENPP2, SLC10A1, CXCR3 | BDKRB2 344/4885OPRL1 264/4885OPRM1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.